Samsung has officially launched blood pressure monitoring capabilities for Galaxy Watch users in the United States, marking the end of a six-year wait since the feature first debuted in South Korea. The Samsung Health Monitor app, now available through the Galaxy Store, enables compatible Galaxy Watch models to track blood pressure readings, though users must still calibrate the device monthly with a traditional blood pressure cuff for accurate measurements.
The Long Road to US Approval
Samsung first introduced blood pressure monitoring on its Galaxy Watch Active2 in South Korea back in 2020, following initial development that began in 2018. The feature utilizes photoplethysmography (PPG) sensors already present in Galaxy Watches to detect subtle changes in blood flow patterns that correlate with blood pressure variations. However, regulatory hurdles in the United States prevented Samsung from offering this capability to American consumers until now. The FDA's stringent medical device approval process required extensive clinical validation studies, which Samsung completed over multiple years to demonstrate the technology's safety and efficacy compared to traditional cuff-based measurements.
According to industry analysts at Counterpoint Research, the delay highlights the complex regulatory landscape for wearable health technologies in the US market. "Samsung's six-year journey to FDA approval demonstrates the rigorous standards applied to digital health tools," noted senior analyst Neil Mawston. The approval process required Samsung to prove that its optical sensors could deliver clinically accurate readings across diverse user populations, accounting for variables such as skin tone, age, and underlying health conditions.
How the Technology Works
The Samsung Health Monitor app transforms existing Galaxy Watch hardware into a blood pressure measurement device through advanced algorithmic processing of optical sensor data. When users initiate a blood pressure reading, the watch's PPG sensors emit green light into the skin and measure how blood vessels expand and contract with each heartbeat. Samsung's proprietary algorithms then analyze these pulse wave variations to estimate systolic and diastolic blood pressure values. The process takes approximately 30 seconds and requires users to remain still with their wrist at heart level for optimal accuracy.
However, the system's reliance on optical sensors introduces inherent limitations that necessitate regular calibration with traditional blood pressure cuffs. Samsung requires users to perform monthly calibrations using a validated arm cuff to maintain measurement accuracy within clinically acceptable ranges. This calibration process involves taking simultaneous readings with both the Galaxy Watch and a conventional blood pressure monitor, allowing the app to adjust its algorithms based on individual physiological characteristics.
Market Impact and Competition
Samsung's entry into US blood pressure monitoring represents a significant milestone in the wearable health technology sector, valued at $27.2 billion globally in 2025 according to Grand View Research. The feature is currently available on Galaxy Watch4, Galaxy Watch5, Galaxy Watch6, and Galaxy Watch7 series devices, covering Samsung's installed base of approximately 8.3 million active Galaxy Watch users in the United States. This positions Samsung ahead of competitors like Apple, which has yet to introduce blood pressure monitoring capabilities in any Apple Watch model despite ongoing research efforts.
Healthcare professionals have expressed cautious optimism about consumer-grade blood pressure monitoring, emphasizing both opportunities and limitations. Dr. Jennifer Miller, a cardiologist at Johns Hopkins Medicine, stated that "while these devices can provide valuable trend data for patients with hypertension, they should complement, not replace, regular clinical monitoring." The American Heart Association estimates that nearly half of US adults have high blood pressure, creating a substantial market for accessible monitoring solutions that could improve treatment adherence and early detection.
Market research from IDC indicates that health monitoring features drive 34% of smartwatch purchasing decisions, with blood pressure tracking ranking as the second most requested feature after heart rate monitoring. Samsung's competitive advantage may prove temporary, however, as Apple and Fitbit parent company Google are reportedly developing similar capabilities for future device releases.
Clinical Accuracy and Limitations
Despite FDA approval, Samsung's blood pressure monitoring technology operates within specific accuracy parameters that users must understand. Clinical validation studies showed the Galaxy Watch achieved measurement accuracy within 5 mmHg of traditional cuff readings in 85% of test cases, meeting FDA standards for consumer health devices. However, the technology performs less reliably for users with certain medical conditions, including atrial fibrillation, severe hypertension, or peripheral artery disease.
The monthly calibration requirement addresses one of the primary challenges in optical blood pressure measurement: individual physiological variation. Factors such as changes in fitness level, weight fluctuations, seasonal variations, and medication adjustments can affect the relationship between optical sensor readings and actual blood pressure values. Samsung's algorithms account for these variables through regular recalibration, though this requirement may limit user adoption compared to fully automated alternatives.
What Comes Next
Samsung plans to expand blood pressure monitoring availability to additional international markets throughout 2026, following successful US deployment and continued regulatory approvals. The company is also developing enhanced algorithms that could potentially extend calibration intervals beyond the current monthly requirement, though FDA re-approval would be necessary for such modifications. Internal Samsung research suggests future Galaxy Watch generations may incorporate additional sensors specifically designed for cardiovascular monitoring, potentially improving accuracy and reducing calibration frequency.
Industry observers expect Apple to respond competitively within the next 18 months, likely coinciding with the Apple Watch Series 11 launch in fall 2027. Google's Pixel Watch team is similarly accelerating blood pressure monitoring development, creating a three-way race for wearable cardiovascular health supremacy. For consumers, Samsung's first-mover advantage in US blood pressure monitoring could drive significant Galaxy Watch market share gains, particularly among health-conscious users seeking comprehensive wellness tracking capabilities beyond basic fitness metrics.